TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Change in C-reactive Protein (CRP) Level
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Interleukin 6 (IL-6) Level
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Tumor Necrosis Factor Alpha (TNF-α) Level
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of adverse events Grade 2 and above
Endpoint domain: Adverse events/effects
Primary endpoint: Progression Free Survival (PFS) at 2 Years
Endpoint domain: Mortality/survival
Primary endpoint: Maximum-tolerated dose (MTD) of gilteritinib
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Insomnia Severity Index (ISI) Mean Total Scores
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: MLD SB Diameter
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Self-Care for Heart Failure Index, Maintenance
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Self-Care for Heart Failure Index, Management
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Self-Care for Heart Failure Index, Confidence
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Migration of the acetabular cup
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Lifestyle risk for type 2 diabetes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Biological risk for type 2 diabetes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Percentage of Patients With On-treatment Gastrointestinal AEs
Endpoint domain: Adverse events/effects
Primary endpoint: Weight gain during hospitalization
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Analgesic Consumption
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Microvascular compartment fraction measured using diffusion MRI (IVIM)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Dynamics of the cerebral blood flow
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Mean Score on Cosmetic Outcome Visual Analog Scale (VAS)
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Change in Left Ventricle End-Systolic Volume Index (LVESVI)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Number of Subjects Experiencing Any System-Related Complications
Endpoint domain: Adverse events/effects
Primary endpoint: Achieving normokalaemia during Correction Phase
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Maintaining normokalaemia during Maintenance Phase
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Percent Change From Baseline in DNA Long Interspersed Nucleotide Element-1 (LINE-1) Demethylation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Composite Complete Response (CRc) Rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Number of Participants With Survival
Endpoint domain: Mortality/survival
Primary endpoint: Efficacy of Carbamazepine in treating Bipolar Disorder
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Safety of Carbamazepine in treating Bipolar Disorder
Endpoint domain: Adverse events/effects
Primary endpoint: Death due to all causes
Endpoint domain: Mortality/survival
Primary endpoint: Change in mDf Value
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Assessment of necrosis/scar
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Assessment of edema
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Assessment of possible intramyocardial hemorrhage
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Percentage of Participants With Positive HER2 Test Result
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Paired Associative Face Name Memory Test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction in gingival margin plaque index
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Physician's Lesion Assessment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Safety of the DynaCAD/UroNAV system
Endpoint domain: Adverse events/effects
Primary endpoint: Measure of adolescent depressive symptoms
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Measure of family conflict around diabetes-specific tasks
Endpoint domain: Life impact
Endpoint subdomain: Personal circumstances
Primary endpoint: User Ability to Operate the APEX Device
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Change in Body Image Disturbance
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Safety and tolerability (heart rate, blood pressure, QTcF, clinical chemistry)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants With Non-serious Adverse Events (Non-SAEs) and SAEs
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Participants With Worst Case Hematology Results by PCI Criteria Post-Baseline Relative to Baseline
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Number of Participants With Worst Case Chemistry Results Relative to Normal Range Post-Baseline Relative to Baseline
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time to 30-day Mortality
Endpoint domain: Mortality/survival
Primary endpoint: pulmonary lesions
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Pharmacokinetics of d6-DM
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Distress (Family Caregiver)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Plasma Area under the Curve (AUC) (0-72 hours)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in urinary frequency
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Radiation dose estimates
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change in PYY levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Combined Endpoint of Syncope, Presyncopal Episode, and Atrioventricular Block
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Increased Intra-abdominal Pressure (IAP) Alarm
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Vaccine Immunogenicity (antibody titers)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Test-Retest reliability of CAPS-5 Total Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Test-Retest reliability of PSSI-5 Total Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Stability of CAPS-5 item-level scores over 6 weeks
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Stability of PSSI-5 item-level scores over 6 weeks
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Detection of ischaemia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Number of Patients With Complete Healing of Ulcer Within 12 Weeks
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time to Complete Healing of Ulcer Within 12 Weeks as Measured by Number of Days From Baseline
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pressure Ulcer Size Measured Using A Ruler at Week 12
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 30 day readmission to the ED
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Proportion of patients with undetectable HCV RNA at 12 weeks post-treatment
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Cumulated rate of alcohol relapse
Endpoint domain: Adverse events/effects
Primary endpoint: Proportion of participants with ≥ 50% leukemic blast reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Improvement of patient outcomes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: improvement in nocturnal hypoxemia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Blood Pressure (BP) measured by Ambulatory Blood Pressure Monitoring (ABPM)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Responder Rate at Month 1
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Normalized Number of Angioedema Attacks
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Change from baseline muscle viscoelastic properties
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change from baseline proprioception
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change from baseline static stretching exercise intensity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Soluble PTK7 measurement in the serum
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Monitoring frequency of AE, SAE and UADEs
Endpoint domain: Adverse events/effects
Primary endpoint: Menopause-specific quality of life
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Satisfaction with decision
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: New Onset Diabetes After Transplant (NODAT)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Acute Rejection
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Lipogenesis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Pain and Disability of the Shoulder
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Number of Participants With Adverse Events as Per Severity
Endpoint domain: Adverse events/effects
Primary endpoint: Successful recoding of accelerometer data
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes in echocardiography
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Changes in functional evaluation tests
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time to 50% gastric emptying
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Percentage of Participants With > 30% Reduction in Mean Parathyroid Hormone
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: quantification of regional renal perfusion
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Rate of Absorption of vitamin D3 to blood
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change in the number of individuals screened as potential living donors
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Change in Knowledge and attitudes in Cardiovascular Health
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Percent Participation
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Percent Completion
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Herniated lumbar disc-related symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of patients reaching remission
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pain in early postoperative period
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reproducibility of lung ventilation imaging
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Morbidity and complications
Endpoint domain: Adverse events/effects
Primary endpoint: Aesthetic outcome evaluation-Patient reported cosmetic outcome results
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Anti-thyroid Peroxidase Antibodies
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Thyroid Hormone Levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Incidence of clinically-suspected DHS
Endpoint domain: Adverse events/effects
Primary endpoint: Incidence of immunologically-confirmed DHS
Endpoint domain: Adverse events/effects
Primary endpoint: Obesity Cure Success Rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Body weight change rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Waist circumference change rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of Study Eyes With ≥7 Decibels (dB) Improvement From Baseline
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Pancreatic Beta Cell Compensation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Safety in patients with JIA on biologics/MTX
Endpoint domain: Adverse events/effects
Primary endpoint: Long-term efficacy in patients with JIA on biologics/MTX
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Augmentation Index-Change from baseline
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change in Visceral Adipose Tissue volume (VAT)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change in Disposition Index
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change in Forced Expiratory Volume in the first second (FEV1%)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Rate of hypertensive disorders of pregnancy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Pregnancy and childbirth outcomes
Primary endpoint: Terminal elimination half-life (t½)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Acceptability as measured by the proportion of mothers who consented to enroll in the trial
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Number of Conversions of Non-inflamed to Inflamed Melanoma
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Percentage of Participants with Minimal Residual Disease (MRD) Negative Status
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Cy cMax Values
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pharmacokinetic parameters (Cmax, AUC0-tlast, AUC0-∞)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Prevalence of patients with AAA
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change From Baseline in 8-Week SBM Frequency Rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Grasping score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Visual motor integration score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: plasma pharmacokinetics of polymorph Form XLI AG-013736
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cause-specific mortality rate for prostate cancer
Endpoint domain: Mortality/survival
Primary endpoint: Adverse discharge disposition
Endpoint domain: Adverse events/effects
Primary endpoint: Change From Baseline Time of Dim Light Melatonin Onset (DLMO)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: OCT findings in eyes with scleral inflammation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Night time (Sleep) Systolic Blood Pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Daytime time (Awake) Systolic Blood Pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Ambulatory status
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Number of patients with normal body temperature
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Shannon's alpha diversity index
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of patients who experience Treatment Success
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improvement of performance on Touchscreen interface
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Total sum breath hydrogen
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Feasibility of MI sessions
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Physical and Functional Quality of Life
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Severity of Restless Leg Syndrome
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change of gut bacteria
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Change of short chain fatty acid concentration in the gut
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Ratings of gastrointestinal comfort
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Reduction of total liver volume
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improvement in Headache Pain Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Level of compliance with clinical practice guidelines
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Creatine kinase dosage in plasma
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Inflammatory cytokines in plasma
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Quantification of mitochondrial DNA in plasma
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: PCI-related Major adverse cardiac events (MACE)
Endpoint domain: Adverse events/effects
Primary endpoint: Feasibility of MILs Generation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cognitive fatigability markers
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Physical fatigability markers (EEG)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Physical fatigability markers (MEG)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Walking speed (time needed to walk 10 m)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Duration Until Viral Shedding Cessation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Weight loss - 5%
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Columbia Suicide Scale
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: World Health Organization Disability Assessment Schedule 2.0 (WHODAS 2.0)
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: number of identified proteins
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: sequence coverage
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Venlafaxine concentration in blood serum (AUC)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Failure of the novel conservative management
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Estimated amount of blood loss
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Safety of hESC-derived RPE cells
Endpoint domain: Adverse events/effects
Primary endpoint: Composite of Rehospitalization Due to Heart Failure and All-Cause Mortality
Endpoint domain: Mortality/survival
Primary endpoint: Dyspnea Self-Assessment at 6 Hours After Initiation of Study Drug
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Dyspnea Self-Assessment at 24 Hours After Initiation of Study Drug
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Patterns of Urinary Bladder Cancer
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Maximum Tolerated Dose (MTD)/ Recommended phase two dose (RP2D)
Endpoint domain: Adverse events/effects
Primary endpoint: Individual clinical responses assessed by RECIST v1.1
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Identification of nitrate reductase-positive bacteria
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes